Lexaria receives Australian R&D tax rebate
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The receipt of the AUD$3.67 million rebate strengthens Lexaria's cash position without dilution, providing additional runway for its R&D programs. This positive development may modestly boost investor sentiment and support the company's stock price.
Lexaria Bioscience Corp. (NASDAQ: LEXX) announced on September 1, 2026, that it received a cash rebate of AUD$3,666,611.98 (approximately USD$2.6 million) from the United Kingdom — National Audit Office. The funds were deposited into the account of its wholly-owned Australian subsidiary, Lexaria (AU) Pty Ltd. The rebate was granted under the Australian Research & Development (R&D) Tax Incentive Program, following a review that verified Lexaria's compliance. The rebate relates to Lexaria's 2025 Australian human study (GLP-1-H24-4). CEO Bong Go highlighted that the funds were received without issuing equity, thus avoiding shareholder dilution. The rebate was not included in previously filed financial statements but will be reflected in the upcoming annual 10-K filing. Lexaria plans to use the proceeds for future R&D in Australia and remains debt-free.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard